Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition

Matthew J. Pianko, Sean M. Devlin, Eric R. Littmann, Aisara Chansakul, Donna Mastey, Meghan Salcedo, Emily Fontana, Lilan Ling, Elizabet Tavitian, John B. Slingerland, Ann E. Slingerland, Annelie Clurman, Antonio L.C. Gomes, Ying Taur, Eric G. Pamer, Jonathan U. Peled, Marcel R.M. van den Brink, Ola Landgren, Alexander M. Lesokhin

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity after upfront treatment have superior outcomes compared with those who remain MRD1. Recently, associations have been shown between specific commensal microbes and development of plasma cell disorders. Here, we report the association between intestinal microbiota composition and treatment outcome in MM. Microbiota composition of fecal samples collected from 34 MM patients after induction therapy and at the time of flow cytometry–based bone marrow MRD testing was determined by 16S ribosomal RNA sequencing. We observed a higher relative abundance of Eubacterium hallii in the 16 MRD2 patients relative to the 18 MRD1 patients. No association was observed between microbial relative abundance and autologous stem cell transplantation history or MM paraprotein isotype. No differences in microbiota a diversity were observed between MRD2 and MRD1 patients. The potential association of microbiota composition with treatment response in MM patients is an important parameter for additional correlative and clinical investigation.

Original languageEnglish (US)
Pages (from-to)2040-2044
Number of pages5
JournalBlood Advances
Issue number13
StatePublished - 2019
Externally publishedYes

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition'. Together they form a unique fingerprint.

Cite this